AQS — Aequus Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- CA$0.66m
- CA$7.23m
- CA$0.58m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.14 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -407.46% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 2.59 | 2.71 | 1.38 | 0.25 | 0.58 | n/a | n/a | -18.58% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on developing and commercializing, differentiated products in ophthalmology. Its pipeline products include PAUL Glaucoma Implant, ZIMED PF, and REV-0100 / ReVision. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease. PAUL has introduced many design features and unified these into one device and offers a solution for patients with moderate to severe glaucoma. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. REV-0100 works by reducing levels of a toxic lipid called lipid bisretinoid, which accumulates within the retina in material called lipofuscin.
Directors
- Douglas Janzen CHM (51)
- Ann Fehr CFO (50)
- Grant Larsen OTH
- Christopher Clark DRC
- Anne Stevens DRC
- Jason Flowerday IND
- Stuart Fowler IND
- Marc Lustig IND (47)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 3rd, 2013
- Public Since
- March 17th, 2015
- No. of Employees
- 12
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 132,634,431
- Address
- Suite 2820, 200 Granville Street, VANCOUVER, V6C 1S4
- Web
- https://www.aequuspharma.ca/
- Phone
- +1 6043367906
- Auditors
- Smythe LLP
Upcoming Events for AQS
Q1 2025 Aequus Pharmaceuticals Inc Earnings Release
Aequus Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Aequus Pharmaceuticals Inc Earnings Release
Similar to AQS
Arch Biopartners
TSX Venture Exchange
Biosyent
TSX Venture Exchange
Cytophage Technologies
TSX Venture Exchange
Decibel Cannabis
TSX Venture Exchange
Delivra Health Brands
TSX Venture Exchange
FAQ
What is the Aequus Pharmaceuticals share price?
As of Today at 19:07 UTC, shares in Aequus Pharmaceuticals are trading at CA$0.01. This share price information is delayed by 15 minutes.
How has the Aequus Pharmaceuticals share price performed this year?
Shares in Aequus Pharmaceuticals last closed at CA$0.01 and the price had moved by -66.67% over the past 365 days. In terms of relative price strength the Aequus Pharmaceuticals share price has underperformed the Toronto Stock Exchange 300 Composite Index by -70.36% over the past year.
What are the analyst and broker recommendations for Aequus Pharmaceuticals?
There is no consensus recommendation for this security.
Find out moreWhat is the Aequus Pharmaceuticals dividend yield?
Aequus Pharmaceuticals does not currently pay a dividend.
Does Aequus Pharmaceuticals pay a dividend?
Aequus Pharmaceuticals does not currently pay a dividend.
When does Aequus Pharmaceuticals next pay dividends?
Aequus Pharmaceuticals does not currently pay a dividend.
How do I buy Aequus Pharmaceuticals shares?
To buy shares in Aequus Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aequus Pharmaceuticals?
As of the previous close price of CA$0.01, shares in Aequus Pharmaceuticals had a market capitalisation of CA$0.66m.
Where are Aequus Pharmaceuticals shares listed?
Here are the trading details for Aequus Pharmaceuticals:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: AQS
What kind of share is Aequus Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Aequus Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aequus Pharmaceuticals share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Aequus Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aequus Pharmaceuticals. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -50.29%.
As of the last closing price of CA$0.01, shares in Aequus Pharmaceuticals were trading -73.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aequus Pharmaceuticals PE Ratio?
The Aequus Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aequus Pharmaceuticals?
Aequus Pharmaceuticals' management team is headed by:
- Douglas Janzen - CHM
- Ann Fehr - CFO
- Grant Larsen - OTH
- Christopher Clark - DRC
- Anne Stevens - DRC
- Jason Flowerday - IND
- Stuart Fowler - IND
- Marc Lustig - IND